Poliomyelitis Clinical Trial
Verified date | January 2014 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
This study is intended to support the registration of IMOVAX Polio in China.
The primary objective of this Pase III trial is to compare IMOVAX Polio to the current
Chinese standard of care (OPV) that is administered following a schedule of 2-3-4 months.
The objective is to demonstrate that after the 3 doses primary series, in terms of
seroprotection rates, IMOVAX Polio is not inferior to OPV. The safety of IPV will be
assessed after each IPV dose.
Status | Completed |
Enrollment | 600 |
Est. completion date | December 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 60 Days to 70 Days |
Eligibility |
Inclusion Criteria: - Aged 2 months (60-70 days) on the day of inclusion into the study - Born at full term pregnancy ( over 36 weeks) with a birth weight = 2.5 kg 2Ibs) or more - Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation - Able to attend all planned clinic appointment and obey and follow all study instructions Exclusion Criteria: - Taking part in another clinical trial during the 4 weeks before the first trial vaccination - Have plans to take part in another clinical trial d during this trial period - Inborn or acquired decreased body natural defense, undertaking treatment that can reduce body's natural defense such as cancer drugs, radiation in the past six months or long term corticosteroid treatment - Systemic reaction to any vaccine component or history of life-threatening reaction to study vaccine or any vaccine with the same ingredient(s) - Prolonged or long time illness that could interfere with study or full participation - Received blood or blood-derived products since birth - Received any vaccine in the 4 weeks before the first trial vaccination is given (except BCG and hepatitis B) - Have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination is given (except DTacP) - Previous vaccination against the poliomyelitis infection with the trial vaccine or another vaccine - History of poliomyelitis infection (confirmed either by symptoms, blood or other laboratory test) - Clinical or serological evidence of systemic illness including hepatitis B, hepatitis C or Human immunodeficiency virus (HIV) - Bleeding disorder or a low platelet which do not allow vaccination into the muscle - Had seizures in the past - Febrile illness (axillary temperature = 37.1°C) or acute illness on the day of inclusion |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine | 1 month post-vaccination 3 | No | |
Secondary | To provide information concerning the safety of IMOVAX Polio™ vaccine | Entire study period | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04989231 -
An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
|
||
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Recruiting |
NCT03890497 -
Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT04693286 -
Clinical Trial of Novel OPV2 Vaccine
|
Phase 2 | |
Completed |
NCT02847026 -
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
|
Phase 4 | |
Completed |
NCT02189811 -
Polio End-game Strategies - Poliovirus Type 2 Challenge Study
|
Phase 4 | |
Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00879827 -
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
|
Phase 3 | |
Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT03614702 -
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
|
Phase 3 | |
Terminated |
NCT04063150 -
Immunogenicity of Intramuscular and Intradermal IPV
|
Phase 4 | |
Completed |
NCT04614597 -
A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
|
||
Completed |
NCT03239496 -
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
|
Phase 3 | |
Completed |
NCT04544787 -
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
|
Phase 2 | |
Completed |
NCT02985320 -
Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
|
Phase 1/Phase 2 | |
Completed |
NCT02274285 -
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
|
Phase 3 | |
Completed |
NCT02291263 -
Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
|
Phase 3 |